US Pharma MarketingFDA should require credentials for psychedelic providers, experts say
Mental health experts urged the FDA at a hearing to set training and prescribing standards for psychedelic therapies. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies…
As the FDA ramps up its effort to accelerate the development of psychedelic therapies, mental health experts on Monday urged the agency to consider certain safety precautions.
The comments came during a four-hour public hearing ...
Source: Endpoints News